Hero

Evrysdi

Evrysdi (risplidam) is FDA approved for the treatment of spinal muscular atrophy (SMA) in infants, children, and adults. SMA is a severe, inherited, progressive neuromuscular disease caused by mutations in chromosome 5q and the resulting SMN protein deficiency causes devastating muscle atrophy and disease-related complications. Evrysdi is an orally administered survival motor neuron-2 (SMN2) splicing modifier that address the underlying genetic cause of SMA to restore SMN protein levels.

Therapeutic Area

Spinal muscular atrophy (SMA) in infants, children, and adults

Acquisition Date

July 2020

Marketer

roche

Seller

PTC Therapeutics